HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Krzysztof Giannopoulos Selected Research

Hematologic Neoplasms (Hematological Malignancy)

1/2022Programmed Cell Death-1 and Its Ligands as Targets for Therapy of Multiple Myeloma Patients.
12/2011Tyrosine kinase inhibitors in hematological malignancies.
7/2010High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma.
8/2005Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Krzysztof Giannopoulos Research Topics

Disease

24B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
07/2022 - 07/2006
16Neoplasms (Cancer)
02/2021 - 08/2005
12Leukemia
04/2021 - 08/2005
9Multiple Myeloma
07/2022 - 02/2008
9Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
02/2019 - 08/2005
5BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
07/2021 - 12/2006
4Hematologic Neoplasms (Hematological Malignancy)
01/2022 - 08/2005
3Psoriasis (Pustulosis Palmaris et Plantaris)
04/2019 - 06/2018
2COVID-19
07/2022 - 01/2022
2Infections
01/2022 - 01/2011
2Arthritis (Polyarthritis)
08/2018 - 12/2017
2Psoriatic Arthritis
06/2018 - 12/2017
2Autoimmune Diseases (Autoimmune Disease)
10/2016 - 12/2015
2Myelodysplastic Syndromes (Myelodysplastic Syndrome)
07/2010 - 02/2008
1Atrial Fibrillation
01/2020
1Hemorrhage
01/2020
1Trisomy (Trisomies)
01/2017
1Persistent Infection
10/2016
1Necrosis
01/2014
1Renal Insufficiency (Renal Failure)
07/2012
1Carcinogenesis
12/2011
1Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
12/2011
1Human Influenza (Influenza)
09/2008
1Chondrosarcoma
01/2008
1Pathologic Complete Response
12/2006
1Residual Neoplasm
12/2006

Drug/Important Bio-Agent (IBA)

9AntigensIBA
12/2013 - 08/2005
8Proteins (Proteins, Gene)FDA Link
11/2020 - 07/2006
6Peptides (Polypeptides)IBA
01/2011 - 08/2005
5HLA-G Antigens (HLA G)IBA
04/2019 - 07/2012
4LigandsIBA
01/2022 - 01/2012
4Thalidomide (Thalomid)FDA Link
03/2015 - 03/2007
3Messenger RNA (mRNA)IBA
07/2022 - 12/2006
3Phosphotransferases (Kinase)IBA
07/2021 - 12/2011
3CytokinesIBA
02/2021 - 12/2017
3ibrutinibIBA
07/2020 - 10/2017
3Imatinib Mesylate (Gleevec)FDA Link
07/2017 - 12/2006
3VaccinesIBA
08/2008 - 08/2005
3Hyaluronic Acid (Hyaluronan)IBA
02/2008 - 08/2005
2Agammaglobulinaemia Tyrosine KinaseIBA
01/2022 - 01/2022
2Bendamustine HydrochlorideFDA Link
01/2022 - 11/2021
2Tyrosine (L-Tyrosine)FDA Link
07/2021 - 12/2011
2Dasatinib (BMS 354825)FDA Link
04/2021 - 01/2021
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
10/2020 - 09/2013
2Neuropilin-1IBA
10/2020 - 09/2013
2Prostaglandins AIBA
04/2019 - 06/2018
2Biomarkers (Surrogate Marker)IBA
08/2016 - 07/2006
2fludarabineIBA
03/2015 - 03/2007
2HLA Antigens (Human Leukocyte Antigens)IBA
01/2015 - 05/2008
2FibromodulinIBA
09/2008 - 10/2006
2EpitopesIBA
09/2008 - 08/2005
2SurvivinIBA
09/2008 - 10/2006
2EnzymesIBA
04/2006 - 08/2005
1mRNA VaccinesIBA
07/2022
1BNT162 VaccineIBA
07/2022
12019-nCoV Vaccine mRNA-1273IBA
07/2022
1AntibodiesIBA
01/2022
1Hemoglobins (Hemoglobin)IBA
01/2022
1venetoclaxIBA
01/2022
1L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
01/2022
1zanubrutinibIBA
01/2022
1Rituximab (Mabthera)FDA Link
01/2022
1Immunoglobulins (Immunoglobulin)IBA
11/2021
1Toll-Like Receptors (Toll-Like Receptor)IBA
02/2021
1EmulsionsIBA
01/2021
1RNA (Ribonucleic Acid)IBA
10/2020
1daratumumabIBA
09/2019
1Biotin (Vitamin H)FDA Link
11/2018
12,6-bis-trifluoromethylbenzoic acid 2- (1- (ethoxycarbonylmethylcarbamoyl)- 3- methylbutylcarbamoyl)allyl esterIBA
11/2018
1Therapeutic UsesIBA
11/2018
1Small Interfering RNA (siRNA)IBA
11/2018
1CCAAT-Enhancer-Binding ProteinsIBA
11/2018
1ThioredoxinsIBA
11/2018
1Protein Disulfide-IsomerasesIBA
11/2018
1Pharmaceutical PreparationsIBA
01/2018
1MicroRNAs (MicroRNA)IBA
01/2017
1Bortezomib (Velcade)FDA Link
08/2016
1Interleukin-17 (Interleukin 17)IBA
12/2015
1Valproic Acid (Depakote)FDA LinkGeneric
01/2015
1GlucocorticoidsIBA
01/2014
1NF-kappa B (NF-kB)IBA
01/2014
1Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
09/2013
1Tyrosine Kinase InhibitorsIBA
12/2011
1Phosphates (Orthophosphate)IBA
12/2011
1Adenosine Triphosphate (ATP)IBA
12/2011
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
12/2011
1Lenalidomide (CC 5013)FDA Link
12/2011
1Protein Subunit VaccinesIBA
07/2010
1Viral AntigensIBA
09/2008
1Cancer VaccinesIBA
08/2008
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
03/2007
1peptide AIBA
12/2006

Therapy/Procedure

11Immunotherapy
11/2020 - 08/2005
9Therapeutics
07/2022 - 12/2006
3Stem Cell Transplantation
11/2007 - 10/2006
2Salvage Therapy
11/2021 - 01/2008
1Precision Medicine
08/2021
1Hematopoietic Stem Cell Transplantation
02/2019
1Injections
08/2008
1Drug Therapy (Chemotherapy)
12/2006